Product
AI AGENTS
INTELLIGENCE SUITE
API, MCP & INTEGRATION
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
Patsnap Eureka Platform
IP Search Agents
IP Drafting Agents
Engineering Agents
Find Solutions with TRIZ
Life Sciences Agents
Materials Agents
SEP Agents
Patsnap Eureka Desktop
BetaAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisProfessional Services
Open Platform
Developer Center
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Webinars & Training
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using Patsnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report From STELLAR's Phase III results to HYPERION and ZENITH: how sotatercept is reshaping PAH treatment across all risk strata and disease stages.
Article | Report Explore the key engineering, operational, and infrastructure tradeoffs between hydrogen fuel cell and battery-electric powertrains for long-haul heavy-duty trucking.
Article | Report Pelacarsen's HORIZON Phase III trial is the first cardiovascular outcomes study for Lp(a) lowering. Explore the mechanism, trial design, and competitive landscape.
Article | Report How does silicon photonics differ from traditional fiber optics for data center interconnects? Engineering breakdown of integration, bandwidth, and cost trade-offs.
Article | Report What engineering challenges must be solved to build a 10MW floating offshore wind turbine? Structural dynamics, mooring, control, and installation — analysed.
Article | Report Cobenfy (xanomeline-trospium) leads a crowded muscarinic agonist pipeline for schizophrenia and Alzheimer's psychosis. Explore competitive readouts, key players, and patent trends for 2026.
Article | Report ViTs vs CNNs for industrial defect detection: how global self-attention compares to local convolution across accuracy, speed, and data requirements.
Article | Report Fazirsiran, ARO-AAT, and gene therapy are reshaping the AATD drug pipeline. Explore Phase 2 data, GalNAc delivery, and what Phase 3 means for liver disease.
Article | Report Key engineering considerations for MRI-compatible medical device design: material selection, lead safety, RF shielding, and adaptive implant strategies. Evidence from 50+ patents.
Article | Report Anito-cel, cilta-cel, ide-cel and next-generation BCMA CAR-T therapies in multiple myeloma: competitive landscape, IP strategy, and clinical signals analysed.
Article | Report How do synchronous and asynchronous motor drives differ for industrial efficiency? A patent-backed analysis covering control architecture, slip losses, and hybrid drive trends.
Article | Report Anito-cel, cilta-cel, ide-cel, and next-gen BCMA CAR-T in multiple myeloma: IP strategy, clinical signals, dual-targeting innovations, and the Gilead/Arcellx competitive landscape.
Article | Report Explore the 2026 green ammonia synthesis technology landscape: electrochemical, plasma, photocatalytic and next-gen Haber-Bosch routes mapped by patent activity.
Article | Report Examine the main reliability challenges of GaN power devices in automotive-grade applications: trapping, gate stack failure, short-circuit robustness, and more.
Article | Report How do orforglipron, oral semaglutide, and CagriSema compare in obesity and T2D? Analyse mechanisms, clinical signals, and IP strategy in the oral GLP-1 race.